Funded Healthcare Startups
Across these six most recent healthcare and medical devices financings, one disclosed round stands out: Venture Med Group raised $28M on 2025-11-03, dwarfi…
Across these six most recent healthcare and medical devices financings, one disclosed round stands out: Venture Med Group raised $28M on 2025-11-03, dwarfing the next-largest disclosed amount ($32M by Axon Therapies on 2025-09-28 is actually larger; among the disclosed figures, Axon’s $32M on 2025-09-28 is the top round). The disclosed amounts also cluster at the low end: Enteral Access Technologies posted $660K (2025-11-11) and Vesteck Inc. $350K (2025-11-01), while the smallest disclosed amounts are those two at $660K and $350K.
The timing is tightly windowed: five of the six rounds date from 2025-09-24 to 2025-11-11, with entries clustered across the same two months (September through November 2025). Geographically, the list is split between the United States (Venture Med Group, Axon Therapies, Vesteck Inc., BMI OrganBank) and Europe (Enteral Access Technologies in the United Kingdom; Sencilia in the Netherlands). Stage disclosure is mixed: three rounds are Seed or Series A with disclosed amounts (Enteral Access Technologies $660K; Axon Therapies $32M; plus Seed amounts where disclosed), while two companies show “undisclosed” (Sencilia and BMI OrganBank) and two show “Venture - Series Unknown” (Vesteck Inc. and BMI OrganBank).
Most recent rounds
6 shownRelated listings
Frequently asked
Which disclosed round is the outlier, and how does it compare to the rest of the disclosed amounts?
Axon Therapies’ $32M (2025-09-28) is the largest disclosed round in the six rows, sitting well above Enteral Access Technologies’ $660K (2025-11-11) and Vesteck Inc.’s $350K (2025-11-01). The other disclosed figures (Venture Med Group $28M on 2025-11-03; Seed-stage Enteral Access $660K) remain far below Axon’s level.
Are these financings concentrated in a narrow date window?
Yes. Five of six rounds fall between 2025-09-24 and 2025-11-11, spanning about seven weeks, with two closings in early November (Venture Med Group on 2025-11-03 and Enteral Access Technologies on 2025-11-11) and multiple late-September entries (Axon Therapies on 2025-09-28; Sencilia on 2025-09-25; BMI OrganBank on 2025-09-24).
What does the geography look like—are there city or country clusters?
The U.S. accounts for four of the six entries: Venture Med Group (Plymouth, 2025-11-03, $28M), Axon Therapies (New York, 2025-09-28, $32M), Vesteck Inc. (West Chester, 2025-11-01, $350K), and BMI OrganBank (Winston Salem, 2025-09-24, undisclosed). Europe appears in two entries: Enteral Access Technologies (Liverpool, 2025-11-11, $660K) and Sencilia (Groningen, 2025-09-25, undisclosed).
How much of the list is stage-unclear or amount-undisclosed?
Two of six entries are “undisclosed” amounts: Sencilia on 2025-09-25 and BMI OrganBank on 2025-09-24. Two other entries use “Venture - Series Unknown” (Vesteck Inc. on 2025-11-01 and BMI OrganBank on 2025-09-24), indicating both stage ambiguity and missing amount disclosure in a material share of the recent sample.
Which stages dominate the disclosed slice (ignoring the undisclosed amounts)?
Among disclosed amounts, Seed shows up as Enteral Access Technologies ($660K on 2025-11-11), and Series A shows up as Axon Therapies ($32M on 2025-09-28). Venture - Series Unknown appears with disclosed amount for Vesteck Inc. ($350K on 2025-11-01), while Venture - Series Unknown for BMI OrganBank is present but amount is undisclosed (2025-09-24).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.